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ABSTRACT
In contrast to bacteria that have two release factors,
RF1 and RF2, eukaryotes only possess one unrelated
release factor eRF1, which recognizes all three stop
codons of the mRNA and hydrolyses the peptidyl-
tRNA bond. While the molecular basis for bacte-
rial termination has been elucidated, high-resolution
structures of eukaryotic termination complexes have
been lacking. Here we present a 3.8 Å structure of
a human translation termination complex with eRF1
decoding a UAA(A) stop codon. The complex was
formed using the human cytomegalovirus (hCMV)
stalling peptide, which perturbs the peptidyltrans-
ferase center (PTC) to silence the hydrolysis activity
of eRF1. Moreover, unlike sense codons or bacterial
stop codons, the UAA stop codon adopts a U-turn-
like conformation within a pocket formed by eRF1
and the ribosome. Inducing the U-turn conformation
for stop codon recognition rationalizes how decod-
ing by eRF1 includes monitoring geometry in order
to discriminate against sense codons.
INTRODUCTION
Sense and stop codons are recognized in the decoding cen-
ter of the small ribosomal subunit (SSU) by transfer-RNAs
(tRNAs) and release factors (RFs), respectively. For peptide
elongation, the tRNA is delivered by eEF1A (EF-Tu in bac-
teria) to the aminoacyl-tRNA acceptor site (A-site). There,
base pairing between the codon of the messenger RNA
(mRNA) and the anti-codon of a cognate tRNA at least in
the first two positions results in the formation of a short A-
helix. Its correct geometry is monitored by the evolutionary
conserved ribosomal nucleotides G530, A1492 and A1493
(1,2) according to E. coli (Ec) numbering.
However, for translation termination prokaryotes and eu-
karyotes diverged and employ evolutionary unrelated re-
lease factors and most likely distinct decoding mechanisms.
Bacteria possess two class-I release factors, RF1 for recog-
nition of UAA and UAG stop codons and RF2 for decod-
ing UAA and UGA stop codons (3–5). Both factors con-
sist of four domains and adopt a very similar conforma-
tion when bound to the ribosome (6–9). Domains 2 and 4
form the stop codon “reading head” comprising conserved
amino acids of the so-called recognition loop (PxT-motif
in RF1, SPF-motif in RF2), whereas domain 3 possesses
the highly conserved GGQ-motif that triggers release of the
nascent polypeptide chain in the PTC of the large riboso-
mal subunit (LSU). Notably, in contrast to A-helix forming
sense codons, stop codons adopt a different conformation
when decoded by RFs in bacteria. The third (Wobble) base
is not stacked on the first two bases and instead interacts
with G530 of the 16S rRNA in a distinct conformation. In
this geometry, the identity of the codon is recognized by the
reading head of the RF via a network of hydrogen bonds
between the three individual bases of the stop codon and
specific RF amino acid side chains.
In contrast to bacteria, eukaryotes contain one struc-
turally unrelated class-I termination factor, termed eRF1,
which reads all three stop codons. eRF1 consists of an
N-terminal domain (N domain) necessary for stop-codon
recognition (10), the M domain carrying the conserved
GGQ-motif (11) and a C-terminal domain (C domain),
which mediates the interaction with the class-II termination
factor eRF3 and the ribosome recycling factor ABCE1 (12–
15). eRF1 is delivered to the ribosomal A-site in form of a
ternary complex with the GTPase eRF3. Following stop-
codon recognition by eRF1, eRF3 hydrolyses GTP to GDP
and dissociates from the ribosome (15–17). Subsequently,
eRF1 accommodates into the A-site of the ribosome in an
extended state, positioning its GGQ-motif of the M domain
in the PTC for peptide release (13,18,19). Subsequently, the
ATPase ABCE1 can bind to the ribosome-eRF1 complex
further stimulating peptide release (15) and eventually trig-
gering ribosome recycling by dissociating the ribosome into
subunits (14,20,21). So far, structures have not been of suffi-
ciently high resolution in order to obtain information about
the stop decoding mechanism by eRF1 (13,18,22). How-
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Figure 1. Translation in human cell-free extract. (A) Schematic representation of the individual steps from human HeLa cell culture to a cell-free human in
vitro translation extract. Cells were grown in a large spinner flask. After harvesting and washing of the cells, they were subjected to nitrogen pressure and
disrupted by sudden pressure release. A quick centrifugation step resulted in a crude extract which can be supplemented for optimal performance of mRNA
in vitro translation. Example of in vitro translational stalling optimization for (B) time (C) magnesium acetate concentration and (D) potassium acetate
concentration using Western blotting with anti-HA antibody for detection of tRNA-bound hCMV peptide or free hCMV peptide. Optimal conditions
vary for each extract.
ever, a wealth of biochemical and mutational studies sug-
gest that the highly conserved TAS-NIKS motif (residues
58–64), the GTS-loop (residues 31–33) and the YxCxxxF
motif (residues 125–131) of the eRF1 N domain are impor-
tant for stop-codon recognition (23–26).
Here, we used cryo-EM to report on the structure of
an hCMV stalled human 80S ribosome bound to eRF1.
The hCMV stalling peptide perturbs the PTC to silence
the peptide hydrolysis activity of eRF1. Moreover, the
UAA(A) stop codon adopts a unique U-turn-like confor-
mation within a pocket formed by eRF1 and the ribosome
revealing an important contribution of mRNA geometry
recognition for stop codon decoding in eukaryotes.
MATERIALS AND METHODS
Plasmid constructions
The hCMV-stalling construct depicted in Figures 2A and
3B was cloned into the pT7CFE1 backbone via the
MegaWhop cloning method (27). For the mutational analy-
sis, point mutations to codons encoding for alanine or (only
for selected residues) for other amino acids were introduced
with the same cloning method. The CMV-truncated con-
trol construct that lacks the stop codon (truncated after
the Pro22 codon) was generated in the same way. The ex-
pression plasmid for human eRF1 was obtained by cloning
isoform 1 of the human eRF1 encoding sequence into the
pETDuet-1 backbone via MegaWhop cloning. The con-
struct also contained an N-terminal (His)6-tag for protein
purification and an HRV 3C protease cleavage-site for tag
removal. The Jmjd4-expression plasmid (pET-28a contain-
ing (His)6-tagged Jmjd4) was kindly provided by Sarah
Wilkins/Mathew Coleman (Oxford University) (28).
Human in vitro translation extract
The translation extract was prepared on the basis of
Mikami et al. (29) with significant adjustments (Figure 1A).
HeLa S3 cells were grown to a density of 3.0–5.5 × 105 in
SMEM (Sigma), supplemented with 10% heat-inactivated
FCS (Gibco), Penicillin (100 U/ml)/Streptomycin 100
g/ml (Gibco) and 1x GlutaMAX (Gibco) at 37◦C, 5%
CO2 using a spinner flask (40 rpm). Subsequently, cells
were harvested (2 min, 650x g) and the resulting pellet was
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Figure 2. Isolation and cryo-EM structure of a stalled human 80S ribosome bound to eRF1. (A) Schematic representation of the hCMV stalling mRNA
construct used in the human translation system for 80S-CMV-RNC generation. The final mRNA construct encoded a CrPV IGR IRES sequence for
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washed 3x with Washing Buffer (35 mM HEPES/KOH pH
7.5, 140 mM NaCl, 11 mM Glucose) (1 min, 650x g) and 1x
with Extraction Buffer (20 mM HEPES/KOH pH 7.5/4◦C,
45 mM KOAc, 45 mM KCl, 1.8 mM Mg(OAc)2, 1 mM
DTT). Further, the cell pellet was resuspended in Extraction
Buffer (1.2 × 109 cells/ml) and disrupted by nitrogen pres-
sure (300 psi, 30 min, 4◦C) in a cell disruption vessel (Parr
Instrument). The lysate was mixed with 1/29 volume High
Potassium Buffer (20 mM HEPES/KOH pH 7.5/4◦C, 945
mM KOAc, 945 mM KCl, 1.8 mM Mg(OAc)2, 1 mM DTT),
incubated at 4◦C for 5 min and centrifuged briefly (20 s, 14
000 rpm, 4◦C). Aliquots of the resulting supernatant were
frozen in liquid nitrogen and stored at −80◦C.
In vitro transcription
Plasmids were linearized with SpeI-HF (NEB) in CutSmart
(NEB) buffer at 37◦C overnight and purified (QIAquick
PCR purification kit (Qiagen)) before in vitro transcrip-
tion (tc) to ensure the right length of the mRNA product.
The final mRNA construct encoded a CrPV IGR IRES
sequence for translation initiation, an N-terminal HA-
and (His)6-tag, the well characterized DP75 dipeptidyl-
aminopeptidase B (DPAPB) (30), the hCMV uORF2
stalling sequence and a polyA-tail. The reaction was per-
formed in Buffer tc (40 mM Tris/HCl pH 7.9/4◦C, 20 mM
MgCl2, 0.01% Triton X-100, 2.5 mM Spermidine, 5 mM
DTT, 6.25 mM ATP, 6.25 mM CTP, 6.25 mM GTP, 6.25
mM UTP, 0.2 U/ml RNasin (Ambion)) with home-made
T7 RNA polymerase and 1.5 g mRNA/100 l reaction.
The tc reaction was incubated for 4 h at 37◦C. Additional T7
RNA polymerase was added during incubation. The result-
ing mRNA was purified by LiCl precipitation and stored at
−80◦C.
In vitro translation
In vitro translation (tl) was performed in Buffer tl (24 mM
HEPES/KOH pH 7.5/4◦C, 112.5 mM KOAc, 20.1 mM
KCl, 2.15 mM Mg(OAc)2, 2.5 mM DTT, 0.25 mM GTP,
1.56 mM ATP, 16 mM Creatine Phosphate (Roche), 0.45
g/l Creatine Kinase (Roche), 50 g/ml yeast tRNA,
0.4 mM Spermidine) with 50% (v/v) extract. This mixture
was supplemented with 0.12 mM amino-acid mixture, com-
plete (Promega) and 0.885 U/l RNasin (Ambion). 100
g mRNA/600 l translation reactions was added before
incubation for 20–60 min (depending on the extract) at
30◦C. Translation time, KOAc and Mg(OAc)2 concentra-
tions were optimized for each extract (Figure 1B–D).
Preparation of eRF1-containing RNCs
Human ribosomes were stalled via the nascent hCMV-
peptide and the resulting ribosome nascent chain complexes
(RNCs) were purified essentially as described before (31).
Briefly, the translation reactions were loaded onto 3 ml
sucrose cushion (750 mM sucrose, 50 mM Tris/HCl pH
7.0/4◦C, 500 mM KOAc, 125 mM Mg(OAc)2, 0.1% Nikkol,
5 mM -Mercaptoethanol, 1/1000 complete protease in-
hibitor (Roche)) for centrifugation (Beckman Coulter TLA
120.2, 100 000 rpm, 45 min, 4◦C). The resulting pellet was
resuspended in 2 ml Buffer A (50 mM Tris/HCl pH 7.0/4◦C,
250 mM KOAc, 25 mM Mg(OAc)2, 0.1% Nikkol, 250
mM sucrose, 5 mM -Mercaptoethanol, 1/1000 EDTA-
free complete protease inhibitor (Roche), 0.2 U/ml RNasin
(Ambion)) and subjected to Co2+-affinity purification. 1
ml TALON Metal Affinity Resin (Macherey & Nagel) was
pre-equilibrated and pre-exposed to a yeast tRNA mix-
ture (10 g/ml) in Buffer A. The beads were washed 3x
with 5 column volume (CV) Buffer A and 1x with 3 CV
Buffer B (50 mM Tris/HCl pH 7.0/4◦C, 500 mM KOAc,
25 mM Mg(OAc)2, 0.1% Nikkol, 250 mM sucrose, 5 mM
-Mercaptoethanol, 1/1000 EDTA-free complete protease
inhibitor (Roche)). Elution of the His-CMV-RNCs was per-
formed with 3 ml Buffer A containing 150 mM imida-
zole. The eluate was again loaded onto a sucrose cushion
and centrifuged (Beckman Coulter TLA 110, 100 000 rpm,
60 min, 4◦C). The pellet was resuspended on ice in 25 l
Buffer C (50 mM Tris/HCl pH 7.0/4◦C, 100 mM KOAc,
6 mM Mg(OAc)2, 1 mM DTT, 1/200 EDTA-free complete
protease inhibitor (Roche), 0.2 U/ml RNasin (Ambion)),
briefly centrifuged (13 000 rpm, 1 min, 4◦C), aliquoted,
frozen in liquid nitrogen and stored at −80◦C. Stalling effi-
ciency and eRF1 co-purification was monitored in the fi-
nal sample via SDS-PAGE and Western blotting. CMV-
truncated control RNCs were prepared accordingly.
Mutational-screening
Mutated hCMV-(stalling) constructs were in vitro tran-
scribed and translated as described above. Incubation of
the translation reaction was terminated by the addition of
1x SDS Sample Buffer. Stalling efficiency after 10, 20, 30
and 40 min at 37◦C was analysed via SDS-PAGE and sub-
sequent Western blotting.
eRF1 expression, purification and in vivo hydroxylation
Co-expression of eRF1 and Jmjd4 was performed in E.coli
BL21 (DE3) for in vivo hydroxylation of eRF1 at K63.
The cells were grown to an OD600 = 0.6 at 37◦C and
temperature-adjusted for subsequent expression at 18◦C
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
translation initiation, an N-terminal HA- and (His)6-tag, the well characterized DP75 dipeptidyl-aminopeptidase B (DPAPB) (30), the hCMV uORF2
stalling sequence and a polyA-tail. The termination site relevant for the Stop23Ala mutated construct is underlined. (B, C) Western blots of purified
human RNCs programmed with the hCMV mRNA shown in (A) or programmed with truncated mRNA (harbouring no stop codon in the A-site). Signal
detection was performed with anti-HA antibody for detection of (B) peptidyl-tRNA or (C) anti-eRF1 antibody. (D) Cryo-EM structure of the eRF1-bound
human 80S-CMV-RNC at 3.8 Å resolution. The colour code for mRNA, tRNA and the eRF1 domains is given. (E) Section of (D) focusing on the hCMV
peptidyl-tRNA. (F) Top view section of the human eRF1 bound 80S-CMV-RNC cryo-EM structure. (G) Molecular models of (F). For docking, the model
of the human ribosome POST structure (pdb code: 5AJ0) and the crystal/NMR structures of human eRF1 (pdb codes: 3E1Y-A, 2KTV) were used. (H, I)
Molecular models displaying (H) all 3 eRF1 domains and (I) ribosomal contacts of human eRF1.
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Figure 3. Mechanism of termination silencing by nascent hCMV peptide. (A) Schematic representation of the gp48/UL4 mRNA illustrating expression
regulation of gp48/UL4 by leaky scanning of uORF2. (B) Ribosome stalling on the hCMV uORF2 leads to gp48/UL4 repression. (C) Identification of
arrest-defective amino acid substitutions within the hCMV stalling peptide indicated by decreased amount of hCMV peptidyl-tRNA and accumulation of
free peptide detected by Western blotting. (D, upper left) Overview of eRF1, peptidyl-tRNA and ribosomal proteins uL22 and uL4 labelled and coloured
distinctively. (D, lower left) EM density section revealing the helical structure which is formed by the nascent hCMV peptide within the upper part of the
ribosomal tunnel. (D, right) Same section, showing H133 of uL22 and nucleotides of the ribosomal tunnel wall which interact with the helical part of the
nascent chain (arrows). (E) Position of the eRF1 GGQ-motif and the peptidyl-tRNA within the PTCs. (F) Comparison of the position of the bacterial RF2
and the human eRF1 GGQ-motifs and the peptidyl-tRNAs within the PTC. (G) eRF1-stabilizing position of Hs A4510 (Ec A2602). (H-K) Comparison
of the position of Hs U4493 (Ec U2585) in (H) the hCMV stalled ribosome complex, (I) the human ribosome in the POST state, (J) the prokaryotic
pre-termination complex and (K) the ErmCL stalled ribosomal complex.
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overnight. After 20 h, cells were harvested, frozen in liq-
uid nitrogen and stored at −80◦C. Lysis Buffer (50 mM
HEPES/KOH pH 7.5/4◦C, 500 mM NaCl, 5 mM imida-
zole, 5 mM -Mercaptoethanol) was added to the pellet
and cells were disrupted in a Microfluidizer (model 110I
lab homogenizer, Microfluidics) at 3x 15 000 psi. The lysate
was cleared (SORVALL, SS-34, 13 500 rpm, 30 min, 4◦C).
The resulting supernatant was incubated with TALON
Metal Affinity Resin (Macherey & Nagel) beads for 1.5
h at 4◦C. Beads were washed with 40x CV WashBuffer
(50 mM HEPES/KOH pH 7.5/4◦C, 500 mM NaCl, 20
mM imidazole, 5 mM -Mercaptoethanol), before incu-
bation with homemade HRV 3C protease in Buffer E (50
mM HEPES/KOH pH 7.5/4◦C, 200 mM NaCl, 1 mM -
Mercaptoethanol, 2.5 mM MgCl2) for 1 h at 4◦C was per-
formed for elution of the tag-free human eRF1 protein. The
protein was aliquoted, frozen in liquid nitrogen and stored
at −80◦C. Samples were taken throughout the purification
procedure for analysis via SDS-PAGE and Western blot-
ting. In vivo hydroxylation of eRF1 at C4 of K63 was mon-
itored via MS/MS.
Cryo-grid preparation
0.1 pmol/l eRF1-CMV-RNCs were incubated with 5x
molar excess of purified and hydroxylated eRF1 to pre-
vent ligand-dissociation from the ribosome. This sample
(20 mM HEPES pH 7.5/4◦C, 100 mM KOAc, 2.5 mM
Mg(OAc)2, 0.25 mM spermidine, 2 mM DTT, 0.06 U/l
RNasin (Ambion), 1/625 EDTA-free complete protease in-
hibitor (Roche)) was applied to 2 nm pre-coated Quantifoil
R3/3 holey carbon supported grids and vitrified using a Vit-
robot Mark IV (FEI Company).
Cryo-electron microscopy and single particle reconstruction
Data collection was performed on a Titan Krios TEM (FEI
Company) equipped with a Falcon II direct electron de-
tector, operated at 300 keV using the EPU software (FEI).
The magnification settings resulted in a pixel size of 1.062
Å/pixel. The data set was provided with the semi-automatic
software EPU (FEI Company) with a dose of 5 e−/Å2 per
frame for frames 0–3 and 10 e−/Å−2 per frame for frames
4–6 at defocus values between 1.0 and 2.7 m. Data were
collected in a series of 7 frames (numbered 0–6) whereof
frames 3–6 were excluded for the final reconstruction for
limitation of the effective dose. The three remaining frames
were aligned and summed up using Motion Correction soft-
ware (32). Automatic particle detection was performed by
the program SIGNATURE (33). Initial alignment of the
obtained 255 253 particles was done using a human 80S
ribosome as reference structure. Data processing and sin-
gle particle analysis were done using the SPIDER software
package (34). Noise and non-ribosomal particles (35,062;
14%) were removed from the data set by further unsuper-
vised 3D sorting (35). Particles lacking ligand or P-tRNA
density were excluded from the final data set. The remain-
ing particles (33 165; 13%) were refined to an average reso-
lution of 3.8 Å (FSC0.143) and a local resolution extending
to 3.6 Å for the core of the ribosome as computed using
ResMap (36) (Supplementary Figure S1). Throughout the
refinement, a frequency-limited (truncation of frequencies
higher than 8 Å) refinement protocol was used to prevent
potential over-fitting (37). The final volume was subjected
to B-factor sharpening using the program EM-BFACTOR
(38).
Molecular model building
The initial model of human eRF1 was based on the crys-
tal structure by Cheng et al. (12) (pdb code: 3E1Y-A).
The missing minidomain herein was added from the NMR
structure of the eRF1 C domain (pdb code: 2KTV). The
initial models for the ribosomal rRNA and proteins were
based on the cryo-EM reconstruction of the human ri-
bosome in the POST state (19) (pdb code: 5AJ0). All
models were initially fitted to the electron density using
UCSF Chimera (39) and adjusted according to the fea-
tures of the electron-density using Coot (40). Modelling
was followed by refinement using the real-space refine tool
of the PHENIX software package (41). Here, default set-
tings of the PHENIX command phenix.real space refine
model.pdb map.ccp4 were used.
Further, we validated the quality of the eRF1-fit by cal-
culating the cross-correlation (CC) between the extracted
density and our model using UCSF Chimera (39). The
CC-values increased when comparing the initial models
(individual domains of the human eRF1 crystal structure
docked into the isolated density) with the refined model
(0.73–0.76 for the N domain; 0.66–0.68 for the M domain,
0.39–0.70 for the C domain). The significant increase for the
CTD CC-value is explained by the lack of the minidomain
and the C-terminal helix in the crystal structure.
Figure preparations
Figures depicting atomic models with and without density
were prepared using UCSF Chimera (39).
RESULTS AND DISCUSSION
Isolation and cryo-EM of a stalled human 80S ribosome
bound to eRF1
We employed the stalling sequence of the hCMV gp48 up-
stream open reading frame 2 (uORF2) (13,42,43) in or-
der to obtain a ribosome-eRF1 complex suitable for struc-
tural analysis using cryo-electron microscopy (cryo-EM).
The nascent hCMV-peptide stalls the ribosome in a pre-
termination state with a UAA stop codon positioned in the
ribosomal A-site. Moreover, hCMV-stalling prevents pep-
tide release and thus leads to an accumulation of ribosome-
bound eRF1 (44). For the purification of stable human ter-
mination complexes, we developed and optimized a robust
human cell-free translation system based on HeLa cell ex-
tracts (Figure 1). Notably, we used the cap-independent
cricket paralysis virus intergenic region internal ribosomal
entry site (CrPV IGR IRES) for translation initiation since
this IRES does not require any initiation factors (45). The
cell-free system was programmed with mRNA encoding the
hCMV stalling peptide and an additional (His)6 affinity tag
at the N-terminus (Figure 2A) for purification of the stalled
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RNCs carrying the UAA stop codon in the A-site. The iso-
lated RNCs displayed a single band for the hCMV-stalled
peptidyl-tRNA in Western blots, indicating the homogene-
ity of the preparation (Figure 2B). Moreover, in contrast to
RNCs that were stalled using a truncated mRNA (without
a stop codon in the A-site), the hCMV-RNCs co-purified
with stably bound endogenous eRF1 (Figure 2C).
For structure determination this preparation was sub-
jected to cryo-EM and single particle analysis in the pres-
ence of excess recombinant human eRF1 in order to main-
tain a high ligand occupancy on the RNCs. Excess eRF1
was in vivo hydroxylated at Lys63 by co-expression with
Jmjd4, a 2-oxogluterate and Fe(II)-dependent oxygenase.
This post-translational modification by Jmjd4 was previ-
ously shown to be endogenously present and required for
optimal translation termination efficiency (28). After in sil-
ico sorting of the data set into homogeneous subpopula-
tions a final sub-data set of 33 165 particles was obtained,
yielding a 3D reconstruction with an average resolution of
3.8 Å (Supplementary Figure S1A). As expected, the elec-
tron density map displayed the typical appearance of a hu-
man ribosome as reported previously (19,46,47), but also
showed additional density for the peptidyl-tRNA in the P-
site and in the exit tunnel of the ribosome, as well as for
eRF1 bound in the A-site (Figure 2D and E). The overall
conformation of the ribosome in the pre-termination state
resembles the post-translocation (POST) state, in which the
ribosomal subunits are not rotated with respect to each
other (19), however, with the stalk base (rRNA helices
H43/H44) moved inwards as observed previously for eRF1
and eRF1/ABCE1 containing complexes (13,19).
eRF1 adopts an extended conformation, reaching into
the A-site decoding center of the SSU with the N domain
while the M domain is oriented towards the LSU position-
ing the GGQ-motif in the PTC (Figure 2F) (13,18). For
molecular analysis, we docked the molecular model for the
human ribosome (19) into our density (Supplementary Fig-
ures S2A, S2B) and built a model for ribosome-bound eRF1
based on the crystal structure of eRF1 in complex with
eRF3 (Figure 2G and H and Supplementary Figure S3A–
3D) (12). The main contacts of eRF1 with the ribosome in-
volve all three domains and predominantly involve riboso-
mal RNA, with the exception of a few contacts to the ri-
bosomal proteins eS27 and uL11 via the -helix forming
C-terminal tail of eRF1 (Figure 2I, Supplementary Figure
S3E–3G).
Termination silencing by the nascent hCMV peptide
The hCMV peptide is encoded in its native mRNA as a
small ORF upstream of the gp48 ORF and when translated
it induces ribosome stalling at its own termination, which
in turn prevents ribosome scanning and thereby represses
expression of the downstream gp48 ORF translation (Fig-
ure 3A and B). We investigated the contribution of the sin-
gle amino acid residues of the hCMV peptide to the stalling
activity in our human cell-free system using scanning mu-
tagenesis. In agreement with previous data (43,48) the most
dramatic stalling compromising effects were observed for
the mutation of the two C-terminal prolines 21/22, validat-
ing their importance for the stalling mechanism in our sys-
tem (Figure 3C).
The hCMV peptide is clearly resolved in our structure
from the PTC to the tunnel constriction (formed by uL22
and uL4 ∼30 Å from the PTC), thereby encompassing all
residues that contribute to the stalling activity (43,44,48);
from the most C-terminal Pro22 to Ser7 near ribosomal
protein uL22 (Figure 3D). The density revealed that the
largest part of the peptide adopts an -helical conforma-
tion and engages in several interactions with the riboso-
mal tunnel (Figure 3D). Several nucleotides of the tun-
nel wall (numbering of Homo sapiens (Hs) is according to
Behrmann et al. (19)) participate in these interactions (Hs
U4494, Ec U2586; Hs A3879, Ec A2062; Hs U4517, Ec
2609; Hs G3875, Ec G2058) and at the N-terminal end of
the -helix Ser7 reaches the most distal His133 of ribosomal
uL22 (Figure 3D).
The GGQ-motif of eRF1 was found in a position in-
distinguishable from the position observed in the bacterial
RF-ribosome complexes (Figure 3E and F and Supplemen-
tary Figure S2C) (9). Given that the GGQ-mediated re-
lease mechanism is indeed conserved between eukaryotes
and prokaryotes, we conclude that eRF1 is properly posi-
tioned in its active conformation also when termination is
stalled by the hCMV peptide, as observed before at lower
resolution (13). Compared to the bacterial pre-termination
complex (9), the ester bond between A76 of the tRNA and
the C-terminal Pro22 also appears to be in its canonical po-
sition. In bacteria, it has been shown that two rRNA nu-
cleotides, Ec A2602 and Ec U2585, within the highly con-
served PTC are required for release activity (49). Ec A2602
stabilizes the GGQ containing loop of bacterial release fac-
tors (8) and, analogously, we find an equivalent situation in
the human complex where Hs A4510 (Ec 2602) stacks upon
the side chain of Phe190 of eRF1 (Figure 3G, Supplemen-
tary Figure S2D).
In contrast, we observed a drastically changed conforma-
tion for Hs U4493 (Ec U2585) (Figure 3H) when compar-
ing to its canonical position in another human ribosome
structure (Figure 3I) (19) or in a bacterial pre-termination
complex (Figure 3J) (9). Specifically, Hs U4493 is flipped
by approximately 90◦ most likely due to a steric clash with
the penultimate Pro21 of the hCMV peptide. This unusual
conformation has been observed before for U2585 in the
context of the bacterial drug-dependent stalling peptide
ErmCL (Figure 3K) (50), where the C-terminal residues
of the ErmCL nascent peptide chain adopts a similar path
compared to the hCMV peptide. It is very unlikely that Hs
U4493 in this conformation can still participate in the re-
lease reaction. Therefore, we suggest that the rotation of
Hs U4493 contributes silencing of the PTC release activ-
ity. This would also rationalize the lack of hCMV medi-
ated stalling when replacing the stop codon with a sense
codon (Figure 3C) since mutations of Ec U2585 have severe
effects on termination but not on peptide bond formation
(49). Taken together, -helix formation of the hCMV pep-
tide combined with the restricted geometry of the residues
Pro21 and Pro22 positions the peptide such that the PTC is
perturbed and loses its ability to support release activity of
an otherwise productively positioned GGQ-loop of eRF1.
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Figure 4. U-turn-like geometry of the UAA stop-codon bound by eRF1 and the ribosome. (A) Human UAA(A) stop-codon (red) positioned in a cavity be-
tween eRF1 (green) and the ribosomal bases Hs G626 (Ec G530) and Hs A1825 (Ec A1493) (gray). (B) EM density revealing the geometry of the mRNA
sequence UAA(A) during stop codon recognition. (C–F) Comparison of the human stop codon mRNA geometry with the known UNR-type U-turn
structures (D) yeast anticodon loop (purple) and (E) Ec 23S rRNA (1082–1086) (turquois). (F) Schematic representation of (C–E). (G–J) Comparison of
the A-site mRNA geometry during (G) human UAA stop codon recognition (H), Thermus thermophilus (Tt) UAA stop codon recognition (light orange)
and (I) Tt UAC sense decoding (light blue). (J) Schematic representation of (G–I). (K–N) Comparison of the h44 (Hs A1824 (Ec A1492), Hs A1825 (Ec
A1493))/H69 (Hs A3731 (Ec A1913)) states during (K) human UAA stop codon recognition, (L) Tt UAA stop codon recognition and (M) Tt UAC decod-
ing. (N) Schematic representation of (K–M). (O) Interactions of the eRF1 TAS-NIKS motif (residues 58–64) with the mRNA/rRNA. The hydroxylation
site of K63 is located at C4 (*). (P) Interactions of the eRF1 YxCxxxF (residues 125–131) motif with the mRNA/rRNA. (Q) Interactions of the eRF1
GTS (residues 31–33) motif with the mRNA.
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The UAA(A) stop codon resembles a U-turn conformation
The N domain of eRF1 reaches into the decoding center
of the SSU and creates a tight pocket to accommodate the
UAA stop codon as well as the fourth nucleotide (A4) im-
mediately following the stop codon (Figure 4A, Supplemen-
tary Figure S4). Notably, compared to the geometry that
was observed for sense codon and bacterial stop codon de-
coding, the eukaryotic stop codon adopts a dramatically
different conformation, namely, that resembling the geom-
etry of a classical RNA U-turn motif of the UNR-type
(Figure 4A and B) (51). Formation of the U-turn results
in shortening of the mRNA, which is in agreement with
a smaller toeprinting signal observed upon eRF1 binding
(16).
The observed stop codon geometry is stabilized by the
characteristic H-bond pattern of an UNR-type U-turn be-
tween the first U (U1) and the third phosphate group as well
as between the 2′-hydroxyl group of the first ribose and the
N7 of the third base that is always a purine (A3 in our case)
in this class of turns (Figure 4C–F). This geometry is very
similar to other U-turns of the same type that have been
found, for example in tRNA anticodon loops as well as in
the 23S ribosomal RNA (Figure 4D and E). This distinct
conformation of the eukaryotic stop codon also results in
a unique mode of interaction with the ribosome and the
release factor, when compared to sense codons or bacte-
rial stop codons during decoding (Figure 4G–J). In bacte-
ria the ribosome stabilizes the third base of the stop codon
by a stacking interaction with Ec G530 (6–9). In case of
the eukaryotic stop codon Hs G626 (Ec G530) stacks onto
the fourth base (A4) allowing for formation of the U-turn
between U1 and A3 (Figure 4A). Moreover, the eukary-
otic stop codon stacks onto the flipped-out Hs A1825 (Ec
A1493), while Hs A1824 (Ec A1492) remains within helix44
(h44) of the SSU rRNA (Figure 4K–N). Conversely, in bac-
terial stop codon recognition A1493 remains in h44 and
only A1492 flips out (6,7,9), where it contributes to the po-
sitioning of A3 of the stop codon on Ec G530, but does not
engage in any stacking interaction (Figure 4L). For sense
codons, both A1492 and A1493 flip out of h44 to insert into
the minor groove of the codon-anticodon helix, forming an
A-minor interaction (Figure 4M).
In addition to the ribosome, all three previously identi-
fied conserved motifs of the eRF1 N domain contribute to
the formation of the stop codon binding pocket as well as
establishing interactions with the ribosome (Figure 4O–Q):
Almost the entire TAS-NIKS motif (residues 58–64) lines
the stop codon on top from Thr58 to Lys63, while residues
Ala59, Ile62 and Ser64 rather stabilize the loop conforma-
tion of eRF1, and the following Arg65 and Arg68 interact
with ribosomal RNA (52). The YxCxxxF motif (residues
125–131) of eRF1 forms the middle part of the binding
pocket and contributes to the stabilization of the flipped out
Hs A1825 which is in agreement with a role of eRF1 in in-
fluencing the conformation of this ribosomal base (53). The
region of eRF1 from Tyr125 to Asp128 is positioned in di-
rect proximity to the stop codon, whereas Asn129, Lys130
and Phe131 are oriented away. The GTS motif from Gly31
to Ser33, in particular Thr32, closes the binding pocket near
A3 of the stop codon.
Recognition of the stop codon and discrimination against
sense codons
How are the three stop codons UAA, UGA and UAG dis-
tinguished from sense codons? A large contribution is ap-
parently provided by the geometry resembling the UNR-
like U-turn motif (51), which is required to optimally fit
into the pocket formed between the ribosome and eRF1.
Having the base U in the first position is mandatory for sta-
bilizing this geometry, and, in addition U1 is found in hy-
drogen bonding distance to Lys63 within the TAS-NIKS
motif of eRF1 (Figure 5A). Consistently, a direct contact
between U1 and Lys63 has been suggested before based on
chemical cross-linking data (54). At this resolution, modifi-
cations like the hydroxylation of Lys63 (C4) cannot be as-
signed. However, since this modification improves transla-
tion termination efficiency, we speculate its involvement in
the proper orientation of the K63 side chain to improve base
discrimination efficiency at position 1 of the stop codon.
Purines in position 1 would be too large for the pocket and,
like cytosine in position 1, would not allow for a stable
UNR-turn geometry. Moreover, cytosine would not allow
the equivalent hydrogen bonding interactions with Lys63 of
eRF1.
The second position in a UNR-turn can in principle
be occupied by any base, however, in our structure A2 is
stacked between A3 of the stop codon and Hs A1825 of
h44 (Figure 5B). Such stacking interaction is more stable
for purines than for pyrimidines (55). Further, A2 interacts
with the YxCxxxF motif, likely forming a direct contact
with Cys127 that would be possible only with the purines
A and G, thus further discriminating against pyrimidines
in position 2. Although we do not see any density for the
nearby Glu55 of eRF1, it is likely that it adopts a canonical
rotamer conformation to interact with the amino groups of
A2 and/or A3 (Figure 5B). This interaction would not be
possible with guanosine which may explain why eRF1 does
not decode UGG. A role of Glu55 in discriminating against
two Gs in position 2 and 3 would be in agreement with pre-
vious findings suggesting the participation of Glu55 in rec-
ognizing the identity of the bases in these positions (56,57).
The third position in a UNR-turn is always a purine,
therefore, meeting the requirement in this position to ex-
clude pyrimidines and allowing only adenosine or guanine.
In addition to the hydrogen bonding with the ribose in po-
sition 1, A3 is stabilized by Thr32 of the eRF1 GTS mo-
tif, an interaction that would also be possible for a G (Fig-
ure 5C). Directly after the stop codon the A in position 4
stacks onto Hs G626 (Ec G530) and thereby provides the
frame for the stable compacted conformation of the stop
codon itself (Figure 5D). A stronger stacking interaction of
purines may explain why eukaryotic stop codons have a sig-
nificant bias in the fourth position, particularly for adeno-
sine (58).
Taken together, we find that eRF1 together with the ribo-
some recognizes the UAA(A) stop codon by a combination
of probing the base identities with monitoring the capac-
ity to adopt a stable U-turn-like geometry, most likely via
an induced-fit mechanism. In contrast, stop codon recogni-
tion in bacteria by two specific release factors relies mostly
on the recognition of the individual bases (6–9). Divergent
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Figure 5. Interaction of eRF1 with the UAA(A) stop codon. (A) The Uracil 1 (U1) nucleotide of the stop codon interacts with N7 of adenosine 3 (A3)
and the A3 backbone phosphate to adopt U-turn geometry of the stop codon. Further, U1 interacts with N61 and K63 of the eRF1 TAS-NIKS motif.
The hydroxylation site of K63 is located at C4 (*). (B) Adenosine 2 (A2) interacts with Hs A1825 (h44) and C127 (YxCxxxF motif). Possible rotamer
conformations of E55 (E55 and E55#) for the interaction with A2 are depicted in light blue. Y125 (YxCxxxF motif) stabilizes the shifted conformation of
Hs A3731 (H69). (C) A3 mainly interacts with T32 (GTS motif) and the 2′OH of U1. (D) Adenosine 4 (A4) stacks on the rRNA base Hs G626 (Ec G530).
Interactions are indicated by dotted lines.
evolution towards U-turn geometry recognition in eukary-
otes would rationalize the unique capacity of eRF1 to rec-
ognize three distinct codons with different base identities in
two positions.
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